AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$GRCE

Opaleye Management Inc. purchased $32K of GRCE (indirect holdings)

Opaleye Management Inc. purchased 15,229 indirectly-held shares of Grace Therapeutics, Inc. (GRCE) at an average of $2.09 ($2.09–$2.10) across 2 trades over 2026-09-08 to 2026-09-09.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Sep 10, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GRCE
Neutral
medium confidence
Mentioned
$GRCE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GRCENeutralLow
01

Why it matters

The filing adds a new data point on insider ownership but does not materially change the investment thesis for GRCE.

02

Market read

Insider purchase is modest; unlikely to drive market moves.

03

What to watch

Potential upcoming clinical trial results or financing events not disclosed in this filing.

Relevance 4/10Novelty 5/10Timing: filing date 2026-09-10

Background

Form 4 filings disclose insider trades; they are primary sources for insider activity.

Company-level read

Ticker impact

$GRCENeutralMedium confidence
Context

Opaleye Management Inc. bought 15,229 shares of Grace Therapeutics (GRCE) for $31.9K, increasing its stake to 2,775,229 shares.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

The transaction is a routine Form 4 filing with a low dollar amount relative to the company's market cap, offering little actionable insight.

Market effects

Sector

None significant; insider activity does not affect sector trends.

Regional

No regional impact.

Global

Limited to GRCE investors.

Counterpoint

What could challenge this read

The purchase could be a strategic move ahead of upcoming corporate actions, but size suggests limited conviction.

Key entities

  • Company
    Grace Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker GRCE.

  • Insider
    Opaleye Management Inc.

    Investment manager reporting a 10% ownership stake.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GRCE insider trading history →

Related articles

AUG 13
$GRCEMed

Grace Therapeutics Announces First Quarter 2027 Financial Results

Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99. 1 Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update Princeton, NJ, August 13, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104

SEC EDGAR 8-K6 min
JUN 18
$GRCEMed

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results

Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20076145_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Pr

SEC EDGAR 8-K4 min